Wednesday, July 8, 2026

Drug profile · INN

epirubicin hydrochloride

epirubicin hydrochloride (EPIRUBICIN HYDROCHLORIDE) is a dna inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — epirubicin hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
2
Data quality
0.84

Quick answer

epirubicin hydrochloride (EPIRUBICIN HYDROCHLORIDE) is a dna inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN epirubicin hydrochloride
Brand EPIRUBICIN HYDROCHLORIDE
Mechanism DNA inhibitor
Target DNA
Route INJECTION
Formulation INJECTABLE

Mechanism of action

DNA inhibitor

Primary target: DNA

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Epirubicin Phase 3 · Chinese Academy of · Hepatocellular Carcinoma
  2. Epirubicin Approved · Chinese Academy of · Carcinoma, Hepatocellular

Related & competitor drugs

  1. acyclovir Human herpesvirus 1 DNA polymerase inhibitor
  2. acyclovir sodium Human herpesvirus 1 DNA polymerase inhibitor
  3. azacitidine Antineoplastic and immunomodulating agents (L01)
  4. bleomycin sulfate DNA inhibitor
  5. busulfan Antineoplastic and immunomodulating agents (L01)
  6. capecitabine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is epirubicin hydrochloride?

epirubicin hydrochloride (EPIRUBICIN HYDROCHLORIDE) is a dna inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for epirubicin hydrochloride?

EPIRUBICIN HYDROCHLORIDE is a marketed brand name for epirubicin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of epirubicin hydrochloride?

epirubicin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.